Acrivon Therapeutics, Inc.

NasdaqGM:ACRV Stock Report

Market Cap: US$193.3m

Acrivon Therapeutics Management

Management criteria checks 2/4

Acrivon Therapeutics' CEO is Peter Blume-Jensen, appointed in Mar 2018, has a tenure of 6.25 years. total yearly compensation is $6.47M, comprised of 9.7% salary and 90.3% bonuses, including company stock and options. directly owns 4.25% of the company’s shares, worth $8.21M. The average tenure of the management team and the board of directors is 2.2 years and 2.5 years respectively.

Key information

Peter Blume-Jensen

Chief executive officer

US$6.5m

Total compensation

CEO salary percentage9.7%
CEO tenure6.3yrs
CEO ownership4.2%
Management average tenure2.2yrs
Board average tenure2.5yrs

Recent management updates

Recent updates

Here's Why We're Not Too Worried About Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Situation

Mar 29
Here's Why We're Not Too Worried About Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Situation

Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans

Oct 05
Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans

Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans

Jun 22
Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans

We Think Acrivon Therapeutics (NASDAQ:ACRV) Can Afford To Drive Business Growth

Feb 22
We Think Acrivon Therapeutics (NASDAQ:ACRV) Can Afford To Drive Business Growth

CEO Compensation Analysis

How has Peter Blume-Jensen's remuneration changed compared to Acrivon Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024n/an/a

-US$64m

Dec 31 2023US$6mUS$629k

-US$60m

Sep 30 2023n/an/a

-US$50m

Jun 30 2023n/an/a

-US$45m

Mar 31 2023n/an/a

-US$37m

Dec 31 2022US$22mUS$536k

-US$31m

Sep 30 2022n/an/a

-US$27m

Jun 30 2022n/an/a

-US$20m

Mar 31 2022n/an/a

-US$19m

Dec 31 2021US$757kUS$430k

-US$16m

Compensation vs Market: Peter's total compensation ($USD6.47M) is above average for companies of similar size in the US market ($USD1.58M).

Compensation vs Earnings: Peter's compensation has been consistent with company performance over the past year.


CEO

Peter Blume-Jensen (61 yo)

6.3yrs

Tenure

US$6,465,973

Compensation

Mr. Peter Blume-Jensen, MD, PhD., serves as a Member of Advisory Board at Kernal Biologics, Inc. Mr. Blume-Jensen is the Founder, Chairman, President, Chief Executive Officer and Acting Chief Scientific Of...


Leadership Team

NamePositionTenureCompensationOwnership
Peter Blume-Jensen
Co-Founder6.3yrsUS$6.47m4.25%
$ 8.2m
Kristina Masson
Co-Founderno dataUS$739.78k0.97%
$ 1.9m
Mary-Alice Miller
Chief Legal Officer1.7yrsUS$697.00k0.034%
$ 66.2k
Rasmus Holm-Jorgensen
Chief Financial Officer2.2yrsUS$2.30m0.088%
$ 170.6k
Eric Devroe
Chief Operating Officer1.8yrsUS$2.18m0.16%
$ 301.9k
Katharine Peterson
Vice President of Finance & Accountingno datano data0.015%
$ 29.6k
Adam Levy
Senior VP and Head of Investor Relations & Corporate Affairsless than a yearno datano data
Bruce Close
Vice President of Quality & Compliance2.2yrsno datano data
Parvin Miah
VP & Head of Human Resources1.4yrsno datano data
Erick Gamelin
Chief Development Officer3.3yrsUS$538.08k0.058%
$ 111.2k
Jesper Olsen
Academic Co-Founderno datano datano data
Joon Jung
VP & Head of Data Science2.2yrsno datano data

2.2yrs

Average Tenure

51yo

Average Age

Experienced Management: ACRV's management team is considered experienced (2.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Peter Blume-Jensen
Co-Founder6.3yrsUS$6.47m4.25%
$ 8.2m
Kristina Masson
Co-Founder6.3yrsUS$739.78k0.97%
$ 1.9m
Jesper Olsen
Academic Co-Founder2.5yrsno datano data
George Demetri
Member of Scientific Advisory Board2.5yrsno datano data
Ivana Magovcevic-Liebisch
Independent Directorless than a yearno data0.012%
$ 22.6k
Sharon Shacham
Independent Director3.7yrsUS$58.13k0.063%
$ 122.5k
Michael Tomsicek
Independent Director1.7yrsUS$68.13k0.063%
$ 122.5k
Charles Baum
Independent Directorless than a yearUS$325.07k0.032%
$ 62.2k
Robert Abraham
Member of Scientific Advisory Board2.5yrsno datano data
David Berman
Member of Scientific Advisory Board2.5yrsno datano data
Derek DiRocco
Independent Director2.6yrsUS$65.00k0.063%
$ 122.5k
Timothy A. Yap
Member of Scientific Advisory Board2.5yrsno datano data

2.5yrs

Average Tenure

57yo

Average Age

Experienced Board: ACRV's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.